Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead

Key Takeaways Kenvue shareholders are expected to receive 0.14625 Kimberly-Clark shares plus $3.50 in cash for each Kenvue share. They are expected to own about 46% of the combined company on a fully diluted basis after closing. Kimberly-Clark has already announced a post-closing organizational structure that would become effective once the acquisition is completed. The buyer, which describes itself as a global personal care leader, is preparing for integration even as the transaction still depends on outstanding approvals. Those remaining conditions matter because Kenvue is not providing forward-looking financial guidance while the deal is pending. Expected transaction benefits may not be realized or may take longer than expected, while the pending transaction could also disrupt the business.Kenvue Inc. Price, Consensus and EPS SurpriseSelf Care remains a pressure point. First-half organic sales in the segment declined 0.9% as volumes fell 2.3%, reflecting lower illness incidence in pediatric pain and cough-and-cold categories. Skin Health and Beauty provided a stronger offset, with first-half organic sales up 4.4% and segment adjusted operating income rising 46.9% to $354 million. Competition across these categories remains broad. The Procter & Gamble Company (PG Quick QuotePG - Free Report) operates Beauty, Health Care and Grooming businesses, including skin and personal care and oral care, which overlap with several Kenvue markets. PG's portfolio breadth makes it a relevant competitive reference point for Kenvue's brand-led categories. The balance sheet adds another layer of risk. Kenvue had $8.5 billion of total debt and $1.1 billion of cash as of June 28, 2026. First-half operating cash flow improved 12.2% to $1.2 billion and free cash flow reached $1 billion, but the 2026 restructuring program is expected to carry approximately $250 million of pre-tax charges before delivering approximately $200 million of annualized pre-tax gross cost savings upon completion. Legal and macro pressures have not disappeared. The Second Circuit vacated the prior acetaminophen judgment in July 2026 and remanded the litigation for further proceedings. Kenvue also remains responsible for certain talc-related liabilities outside the United States and Canada, while annualized gross tariff exposure was estimated at approximately $80 million. Bottom line, major shareholder and U.S. antitrust milestones are complete, but the expected fourth-quarter closing still carries regulatory, operational and financial risk. Weak Self Care volumes, margin pressure, debt, restructuring execution and litigation keep the near-term picture balanced despite stronger cash generation and improving Skin Health and Beauty trends.Kenvue currently carries a Zacks Rank #3 (Hold), a Value Score of C, a Growth Score of C, a Momentum Score of D and a VGM Score of D. Within the Style Score framework, A and B grades are more favorable than C and D grades, while the Zacks Rank remains the first screen for near-term earnings-estimate trends. Kenvue's C and D scores therefore do not add a strong style-based tailwind to its #3 Rank. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.